Updates and Controversies in COVID-19

W. Cameron McGuire, MD, MPH
PCCSM Fellow
UC San Diego Health
COVID Disproportionately Affects At Risk Populations...
The Spread of COVID-19 *Can* Be Slowed/Stopped...

Successful Elimination of Covid-19 Transmission in New Zealand

New Zealand suspects ‘some failure at the border’ after COVID-19 returns

By Dennis Normile  Aug. 12, 2020, 1:45 PM

Hydroxychloroquine is *still* not a miracle drug...

<table>
<thead>
<tr>
<th>STUDY</th>
<th>Location</th>
<th>Study Type</th>
<th>N</th>
<th>STUDY</th>
<th>Location</th>
<th>Study Type</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chen</td>
<td>In Hospital</td>
<td>Case-Cohort</td>
<td>568</td>
<td>Rosenberg</td>
<td>In Hospital</td>
<td>Retrospective</td>
<td>1438</td>
</tr>
<tr>
<td>Gautret 1</td>
<td>In Hospital</td>
<td>Retrospective</td>
<td>42</td>
<td>VA Study</td>
<td>In Hospital</td>
<td>Retrospective</td>
<td>368</td>
</tr>
<tr>
<td>Gautret 2</td>
<td>In Hospital</td>
<td>Retrospective</td>
<td>80</td>
<td>Boulware</td>
<td>PrEP</td>
<td>RCT</td>
<td>821</td>
</tr>
<tr>
<td>Henry Ford</td>
<td>In Hospital</td>
<td>Retrospective</td>
<td>2541</td>
<td>Spanish</td>
<td>PrEP</td>
<td>RCT</td>
<td>2300</td>
</tr>
<tr>
<td>Recovery</td>
<td>In Hospital</td>
<td>RCT</td>
<td>4674</td>
<td>Orchid*</td>
<td>In Hospital</td>
<td>RCT</td>
<td>470</td>
</tr>
<tr>
<td>Solidarity*</td>
<td>In Hospital</td>
<td>RCT</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cavalcanti</td>
<td>In Hospital</td>
<td>RCT</td>
<td>667</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discovery</td>
<td>In Hospital</td>
<td>RCT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

N = 3151

**Annals of Internal Medicine**

**Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19**

A Living Systematic Review

Adrian V. Hernandez, MD, PhD; Yuani M. Roman, MD, MPH; Vinay Pasupuleti, MD, MS, PhD; Joshuan J. Barboza, MSc; and C. Michael White, PharmD

N = 10738
Vaccines are coming...

But probably not from Russia...

<table>
<thead>
<tr>
<th>COVID-19 Vaccine developer/manufacturer</th>
<th>Vaccine platform</th>
<th>Type of candidate vaccine</th>
<th>Number of doses</th>
<th>Timing of doses</th>
<th>Route of Administration</th>
<th>Clinical Stage</th>
<th>Phase 1</th>
<th>Phase 1/2</th>
<th>Phase 2</th>
<th>Phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>University of Oxford/AstraZeneca</td>
<td>Non-Replicating Viral Vector</td>
<td>ChAdOx1-S</td>
<td>1</td>
<td>0, 14 days</td>
<td>IM</td>
<td>Phase 1</td>
<td>NCT04008922</td>
<td>2020-001072-15</td>
<td>2020-001228-32</td>
<td>CICTN8955424</td>
</tr>
<tr>
<td>Sinovac</td>
<td>Inactivated</td>
<td>Inactivated</td>
<td>2</td>
<td>0, 14 days</td>
<td>IM</td>
<td>Phase 1</td>
<td>NCT04538314</td>
<td>NCT04552608</td>
<td>NCT04456595</td>
<td>00016-15-2020</td>
</tr>
<tr>
<td>Wuhan Institute of Biological Products/Sinopharm</td>
<td>Inactivated</td>
<td>Inactivated</td>
<td>2</td>
<td>0, 14 or 0, 21 days</td>
<td>IM</td>
<td>Phase 1</td>
<td>ChCTR2000031809</td>
<td>ChCTR2000032458</td>
<td>ChCTR2000034780</td>
<td></td>
</tr>
<tr>
<td>Beijing Institute of Biological Products/Sinopharm</td>
<td>Inactivated</td>
<td>Inactivated</td>
<td>2</td>
<td>0, 14 or 0, 21 days</td>
<td>IM</td>
<td>Phase 1</td>
<td>ChCTR2000031809</td>
<td>ChCTR2000032458</td>
<td>ChCTR2000034780</td>
<td></td>
</tr>
<tr>
<td>Moderna/NIHAD</td>
<td>RNA</td>
<td>RNA</td>
<td>2</td>
<td>0, 28 days</td>
<td>IM</td>
<td>Phase 1</td>
<td>NCT04283461</td>
<td>NCT04465076</td>
<td>NCT04472427</td>
<td></td>
</tr>
<tr>
<td>BioNTech/Fosun Pharma/Pfizer</td>
<td>RNA</td>
<td>RNA</td>
<td>2</td>
<td>0, 28 days</td>
<td>IM</td>
<td>Phase 1</td>
<td>NCT04283461</td>
<td>NCT04465076</td>
<td>NCT04472427</td>
<td></td>
</tr>
<tr>
<td>CanSino Biological Inc./Biijing Institute of Biotechnology</td>
<td>Non-Replicating Viral Vector</td>
<td>Adenovirus Type 5 Vector</td>
<td>1</td>
<td>0, 28 days</td>
<td>IM</td>
<td>Phase 1</td>
<td>ChiCTR2000031209</td>
<td>ChiCTR2000031209</td>
<td>ChiCTR2000031209</td>
<td></td>
</tr>
</tbody>
</table>

UK
China
China
China
US
US
China
We Don’t Know What We Don’t Know…

From ‘brain fog’ to heart damage, COVID-19’s lingering problems alarm scientists

By Jennifer Couzin-Frankel | Jul. 31, 2020, 1:30 PM

The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings

Ross W Paterson, Rachel L Brown, Laura Benjamin, Ross Nortley, Sarah Wiethoff, Tehmina Bharucha, Dipa L Jayaseelan, Guru Kumar, Rhiain E Raftopoulos, Laura Zambreanu… Show more

Brain, awaa240, https://doi.org/10.1093/brain/awaa240
Published: 08 July 2020  Article history

Original Investigation
July 27, 2020

Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19)

Valentina O. Puntmann, MD, PhD; L. Ludovica Carerj, MD; Imke Wieters, MD; et al

WEB EXCLUSIVE CONTENT: COMMENTARY

Long-term Pulmonary Consequences of Coronavirus Disease 2019 (COVID-19)
What We Know and What to Expect

Salehi, Sana MD; Reddy, Sravanthi MD; Gholamrezazhad, Ali MD  Author Information

Journal of Thoracic Imaging: July 2020 - Volume 35 - Issue 4 - p 87-W89
doi: 10.1097/RTI.0000000000000534

More on Clinical Characteristics of Pregnant Women with Covid-19 in Wuhan, China
A Legacy? Or Cautionary Tale? of COVID-19...

Medical preprint server debuts

By Jocelyn Kaiser | Jun. 5, 2019, 7:00 PM

About medRxiv

medRxiv (pronounced "med-archive") is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

medRxiv is receiving many new papers on coronavirus SARS-CoV-2. A reminder: these are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information.

COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

7802 Articles (6173 medRxiv, 1629 bioRxiv)